Tsuchiya-Kawanoa Y, Sasaki T, Yamaguchi H, et al. - Between October 2014 and November 2016, 58 persons were recruited at 14 institutions in Japan in order to report the updated survival data for a phase I/II study of carboplatin plus nab-paclitaxel (nab-P/C) and concurrent radiotherapy (CRT) in individuals with locally advanced non-small cell lung cancer (NSCLC). A total of 56 of these were assessable for treatment efficiency and safety. At the median follow-up time of 26.0 months, the median overall survival (OS) was not attained and the 2-year OS rate was 66.1%. The median PFS was 11.8 months, and the 2-year PFS rate was 35.9%. Subgroup analysis exhibited no variations in median PFS or OS according to tumor histology or patient age. Long-term follow-up of toxicities did not recognize new safety signals, and during the study period, no treatment-related deaths happened. Hence, concurrent chemoradiation with nab-p/c was safe and gave a long-term survival advantage for individuals with locally advanced NSCLC.